Navigation Links
Sopherion Therapeutics Announces Completion of Enrollment in Phase III Study of Myocet in Metastatic Breast Cancer
Date:3/18/2009

PRINCETON, N.J., March 18 /PRNewswire/ -- Sopherion Therapeutics, LLC, a biopharmaceutical company focused on the development and commercialization of anti-cancer therapies, announced that it completed enrollment in its pivotal Phase III study of nonpegylated liposomal doxorubicin (Myocet(TM)) in metastatic HER-2-overexpressing breast cancer. This is a pivotal Phase III trial of Sopherion's lead product in combination with the current standard of care, paclitaxel (Taxol) and trastuzumab (Herceptin(R)), vs. paclitaxel and trastuzumab alone. Progression-free survival (PFS) is the primary efficacy endpoint, with careful monitoring for cardiac safety.

Dr. Jose Baselga, Chairman & Professor of Medicine, Vall d'Hebron Institute of Oncology (V.H.I.O.), Vall d'Hebron University Hospital in Barcelona, Spain, and principal investigator for the trial, said, "I am pleased to see that the recruitment phase of the Phase III trial has now been completed. This registration trial is based on our recently published, Roche-supported study conducted by the Spanish Breast Cancer Cooperative Group (SOLTI). Results showed that Myocet, in combination with trastuzumab and paclitaxel treatment, yielded an unusually high clinical response rate and time to progression in patients with HER-2 overexpressing breast cancer; the 3 drug combination was well tolerated with no cases of treatment-related symptomatic congestive heart failure. "

Phase III Study Design

The study is a global, randomized, multicenter pivotal Phase III study in 363 patients who have metastatic HER-2-overexpressing breast cancer. Eligibility criteria included no prior chemotherapy for metastatic disease, nor any trastuzumab, anthracyclines or taxanes within the previous 12 months. Eligible patients were randomized to receive either Myocet, paclitaxel and trastuzumab, or paclitaxel and trastuzumab alone in a 1:1 randomiza
'/>"/>

SOURCE Sopherion Therapeutics, LLC
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sopherion Therapeutics Secures $55 Million in Series C Funding
2. Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients
3. FDA Accepts IND for Arno Therapeutics Pan-DAC / Akt Inhibitor, AR-42
4. Sirion Therapeutics Supplemental New Drug Application for Durezol(TM) to Treat Uveitis is Accepted for Review by the FDA
5. United Therapeutics Announces Probable Delay in Approval Timeline for Inhaled Treprostinil (Tyvaso)
6. Cell Therapeutics, Inc. (CTI) Reports 2008 Fourth Quarter and Year End Financial Results
7. Cell Therapeutics, Inc. (CTI) to Present at 8th Annual WBBA Invest Northwest Conference
8. Michael J. Fox Foundation Commits Up To $5 Million for Pre-Clinical Drug Development Under Industry-Exclusive Therapeutics Development Initiative
9. CV Therapeutics Board of Directors Rejects Astellas Tender Offer
10. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End Financial Results on March 16
11. Amicus Therapeutics to Present at the Cowen and Company 29th Annual Healthcare Conference on March 17, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... PARK, Calif. , Feb. 26, 2015 ... released the latest version of the Governance Portal ... accomplish governance, risk and compliance (GRC) tasks across multiple ... also been updated to help customers better align their ... of the Treadway Commission ) requirements. In response to ...
(Date:2/26/2015)... On behalf of biotech client ... Wilentz, Goldman & Spitzer, P.A. (Wilentz) secured a ... Genewiz Inc. in excess of $10 million. The jury ... secrets, and that it improperly hired one or more ... denying motions for judgment notwithstanding the verdict, a new ...
(Date:2/26/2015)... 2015 BioEnterprise today announced that ... than $2 billion in growth funding during the past ... strategic sources, state – including the Ohio Third Frontier ... billion has been raised in the past five years. ... of the BioEnterprise Midwest Healthcare Growth Capital  Report. ...
(Date:2/26/2015)... February 26, 2015 Innovation is ... emerging from unexpected parts of the world and ... From agriculture to manufacturing to health care, disruption ... environmental realities and socio-political trends shake the foundations ... key ingredient for CEOs to survive the next ...
Breaking Biology Technology:Protiviti Governance Portal Helps Companies Drive Governance, Risk and Compliance Productivity Across Multiple Business Units 2Protiviti Governance Portal Helps Companies Drive Governance, Risk and Compliance Productivity Across Multiple Business Units 3Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 2More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 3More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 4One Million Acts of Innovation Canada Creates Partnership with The Economist Events’ Innovation Forum 2
... MOUNTAIN VIEW, Calif., March 24 Based on ... market, Frost & Sullivan recognizes Life Technologies with ... of the Year Award. The company,s size, product ... potential set it apart from any competitor in ...
... March 24 GeneGo, Inc., the leading systems biology ... Centre for Mental Health at the South London and ... has joined the MetaMiner CNS Partnership Program. Professor Simon ... the BRC-MH team for this project. The goal ...
... 24 ViroPharma Incorporated (Nasdaq: VPHM ... negotiated transaction, $45 million principal amount or 18 ... March 2017 for total consideration of approximately $21.2 ... $205 million of principal debt are outstanding.As a ...
Cached Biology Technology:Frost & Sullivan Recognizes Life Technologies for Excellence in the Life Science Research Tools Industry 2Frost & Sullivan Recognizes Life Technologies for Excellence in the Life Science Research Tools Industry 3Frost & Sullivan Recognizes Life Technologies for Excellence in the Life Science Research Tools Industry 4Frost & Sullivan Recognizes Life Technologies for Excellence in the Life Science Research Tools Industry 5The NIHR Biomedical Research Centre for Mental Health London has Joined the MetaMiner CNS Partnership Program 2The NIHR Biomedical Research Centre for Mental Health London has Joined the MetaMiner CNS Partnership Program 3The NIHR Biomedical Research Centre for Mental Health London has Joined the MetaMiner CNS Partnership Program 4ViroPharma Improves Financial Position Through Repurchase of $45 Million Principal Amount of Senior Convertible Notes 2ViroPharma Improves Financial Position Through Repurchase of $45 Million Principal Amount of Senior Convertible Notes 3ViroPharma Improves Financial Position Through Repurchase of $45 Million Principal Amount of Senior Convertible Notes 4
(Date:1/22/2015)... Jan. 20, 2015 NXT-ID, Inc. (NASDAQ: NXTD and ... reports on the recent success of the Wocket™ smart wallet at CES ... smart wallet was named as one of the "11 Hot Products at ... Products Launched At CES So Far" by Newseveryday.com and "The top 10 ...
(Date:1/22/2015)... Report Issued by Small Cap IR. In 2011, Nilson Report,s ... at merchants on the leading payment cards rose to $135.3 ... and prepaid cards reached 6.54 billion.  Eight million credit card ... in 2012, and credit and debit card fraud resulted in ...
(Date:1/22/2015)... 22, 2015 Research and Markets ( ... "Global Wearable Technologies Market and Applications, Opportunities, ... and Forecast 2014-2020" report to their offering. ... devices that can be worn on the user,s ...
Breaking Biology News(10 mins):CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2
... are reporting discovery of unusual liver proteins, found only in ... the hepatitis B virus (HBV) sexually discriminates -- hitting men ... ACS, Journal of Proteome Research , a monthly publication. ... chronic hepatitis B seems to progress and cause liver damage ...
... known for attacking humans and animals, but some viruses ... how hungry viruses, armed with transformer-like weapons, attack bacteria, ... , The Texas A&M researchers, work is published in ... . , The attackers are called phages, or bacteriophages, ...
... Prions are causing fatal and infectious diseases of ... (BSE), scrapie in sheep or Creutzfeldt-Jakob disease in humans. ... have now succeeded in elucidating another disease mechanism of ... and produces increased quantities of cholesterol. Prions need this ...
Cached Biology News:Texas A&M Researchers Examine How Viruses Destroy Bacteria 2The protein Srebp2 drives cholesterol formation in prion-infected neuronal cells 2
Request Info...
The BD OptEIA Rat TNF-alpha ELISA Kit is for the quantitative determination of TNF-alpha in rat serum, plasma and cell culture supernatant....
Request Info...
... Human CD66 acd Recognizes human ... neutrophils and cells in some cases ... with transfectants containing BGPa, NCA and ... Immunogen: Human ...
Biology Products: